Can I Take Glycine with Tirosint?

What Is Tirosint and Why Does It Differ from Standard Levothyroxine?

Tirosint is a brand of levothyroxine sodium formulated as a liquid-filled gelatin capsule (and as a liquid oral solution, Tirosint-SOL). Unlike standard levothyroxine tablets such as Synthroid or generic T4, Tirosint contains only four ingredients: levothyroxine sodium, gelatin, glycerin, and water. That minimal excipient profile was designed for patients whose tablet absorption is disrupted by gastrointestinal conditions, lactose intolerance, or drug-food interactions.

Why Absorption Matters So Much with Levothyroxine

Levothyroxine has a narrow therapeutic index. A shift of as little as 12.5 mcg in daily dose can push TSH outside the target range in sensitive patients. A 2013 study in the Journal of Clinical Endocrinology and Metabolism (N=84) found that switching from levothyroxine tablets to liquid levothyroxine normalized TSH in 75% of patients with persistent hypothyroidism attributed to malabsorption (1).

Tirosint's Advantage Over Tablets

Because the active hormone is already dissolved in the gel capsule, Tirosint bypasses the dissolution step required by tablet formulations. This makes it somewhat less sensitive to co-ingested substances. "less sensitive" does not mean "immune." Calcium, iron, and proton-pump inhibitors still affect absorption when taken simultaneously with Tirosint, though to a lesser degree than with tablets (2).

What Is Glycine and Why Do People Take It?

Glycine is the simplest amino acid. It is synthesized endogenously at roughly 3 g/day, but dietary and supplemental intake can add another 1.5 to 3 g on top of that. Supplement users typically take 2 to 5 g at bedtime for sleep quality, up to 10 g/day for collagen support, and occasionally higher doses in research settings for metabolic health.

Glycine's Mechanisms Relevant to Thyroid Patients

Three mechanisms deserve attention for anyone on Tirosint:

1. Central nervous system sedation via glycine receptors. Glycine acts as an inhibitory neurotransmitter in the brainstem and spinal cord by binding strychnine-sensitive glycine receptors (GlyR). A 2012 randomized crossover trial (N=11) published in Sleep and Biological Rhythms found that 3 g of glycine taken before bedtime reduced self-reported fatigue and improved sleep efficiency scores (3). Hypothyroid patients already experience fatigue; adding a mild sedative supplement without physician awareness may confuse symptom tracking.

2. Glucose and insulin modulation. In a 2016 clinical study (N=60), glycine supplementation at 5 g/day for 3 months improved fasting glucose and insulin sensitivity in patients with type 2 diabetes (4). Thyroid hormone directly regulates glucose metabolism, so any supplement that also moves fasting glucose could complicate the clinical picture for diabetic hypothyroid patients.

3. Collagen and connective tissue synthesis. This is the least pharmacologically relevant mechanism for levothyroxine interactions but is worth noting for completeness. Glycine provides roughly 33% of collagen's amino acid residues, and clinicians sometimes recommend it alongside hypothyroidism treatment because untreated hypothyroidism slows collagen turnover. This is a theoretical benefit, not an interaction concern.

Is There a Direct Pharmacokinetic Interaction Between Glycine and Tirosint?

No confirmed direct pharmacokinetic interaction has been reported in peer-reviewed literature or FDA adverse event databases as of this writing. Pharmacokinetic interaction would require glycine to physically bind levothyroxine in the gut lumen, alter gastric pH, inhibit intestinal transporters, or affect CYP enzymes involved in T4 metabolism.

Absorption in the Gut

Levothyroxine is absorbed primarily in the proximal jejunum via specific amino acid transporters and passive diffusion. Glycine is itself an amino acid and is absorbed through sodium-dependent neutral amino acid transporters (specifically B0AT1, encoded by SLC6A19). At supplemental doses of 3 to 5 g, the question arises whether glycine could compete at the transporter level with levothyroxine uptake.

Levothyroxine is structurally a halogenated thyronine, not a free amino acid, and its intestinal uptake relies on different transporter affinities than glycine. Based on current mechanistic data, direct transporter competition at clinically relevant doses appears unlikely. No published pharmacokinetic study has specifically tested Tirosint co-ingested with glycine.

Hepatic Metabolism and Protein Binding

Once absorbed, levothyroxine is 99.97% protein-bound (primarily to thyroxine-binding globulin, TBG). Glycine is not known to displace T4 from TBG or alter TBG synthesis at typical supplemental doses. Hepatic deiodination of T4 to T3 is performed by deiodinase enzymes (DIO1, DIO2), not CYP450 enzymes, so glycine's negligible CYP450 interactions are irrelevant to that pathway.

The Verdict on Pharmacokinetics

The pharmacokinetic risk appears low. What remains relevant is the pharmacodynamic picture.

Pharmacodynamic Considerations: Where the Real Complexity Lives

Even without a direct absorption interaction, glycine and Tirosint overlap in three clinical domains worth mapping out for prescribers and patients.

Domain 1: Symptom Masking in Thyroid Management

The primary challenge with glycine plus Tirosint is symptom attribution. Both under-replacement of levothyroxine and glycine supplementation produce overlapping effects: improved sleep, reduced fatigue, and better mood. If a patient begins glycine at the same time as a Tirosint dose adjustment, it becomes genuinely difficult to know which intervention is responsible for improvement or worsening.

A TSH drawn 6 to 8 weeks after any change (whether in Tirosint dose or supplement regimen) remains the gold standard for separating these effects. The American Thyroid Association's 2014 guidelines recommend TSH as the primary monitoring marker in levothyroxine-treated hypothyroidism, with a target generally between 0.4 and 4.0 mIU/L for most adults (5).

Domain 2: Glucose Metabolism in Diabetic Patients on Tirosint

Thyroid hormone increases glucose production via hepatic gluconeogenesis and accelerates peripheral glucose utilization. When levothyroxine dose is optimized, this balance normalizes. Glycine's reported insulin-sensitizing effect could, theoretically, shift fasting glucose downward in patients whose diabetes management is already calibrated to their current thyroid status.

For insulin-dependent diabetics, this means glycine supplementation warrants a conversation with the prescribing physician before starting. The clinical risk is small and entirely manageable, but "small and manageable" still requires awareness. A fasting glucose check at the 4-week mark after starting glycine is a reasonable, low-cost precaution.

Domain 3: CNS Sedation Interaction with Other Medications

Glycine's inhibitory neurotransmitter activity becomes more relevant when a patient is also taking benzodiazepines, gabapentinoids, or muscle relaxants. None of those interactions involve Tirosint directly, but many hypothyroid patients are prescribed clonazepam or cyclobenzaprine for associated musculoskeletal symptoms. Stacking glycine on top of those agents could amplify sedation.

This is not a Tirosint-specific concern. It is a general glycine precaution. The physician managing Tirosint dosing should know the patient's full supplement and medication list for exactly this reason.

Dosing, Timing, and Practical Instructions

When to Take Tirosint

The FDA-approved labeling for Tirosint recommends taking the product 30 to 60 minutes before breakfast, with water only, at the same time each day (6). This recommendation exists because even the gel-cap formulation can have its absorption affected by food, coffee, and certain supplements if taken immediately together.

When to Take Glycine

Most users take glycine 30 to 60 minutes before bedtime. That natural timing separation (morning for Tirosint, evening for glycine) means the two products are typically separated by 10 to 16 hours in practice. That gap almost certainly eliminates any residual pharmacokinetic concern.

For patients who use glycine at doses above 5 g/day for collagen support and take it at multiple times, the morning dose should be moved to at least 4 hours after the Tirosint dose as a conservative precaution. Four hours is the standard separation window used for other amino-acid-containing products and levothyroxine.

Dose Considerations for Glycine

No published trial has established a maximum safe dose of glycine in hypothyroid patients specifically. General tolerability data suggest doses up to 31 g/day are well-tolerated in adults without serious adverse effects (7). For the purposes of sleep and metabolic benefit, 3 to 5 g/day is the dose with the most controlled trial support.

Special Populations and Higher-Risk Scenarios

Post-Thyroidectomy Patients

Patients who have had a total thyroidectomy are entirely dependent on exogenous levothyroxine and often have narrower TSH target ranges (particularly those managed for thyroid cancer, where TSH suppression to <0.1 mIU/L may be intentional). Any supplement that could theoretically affect absorption or symptom perception deserves closer monitoring in this group. TSH checks every 6 weeks, rather than the standard 6-month interval, are appropriate when changing the supplement regimen.

Patients with GI Malabsorption

Tirosint was specifically developed for patients with celiac disease, atrophic gastritis, H. Pylori infection, bariatric surgery, or inflammatory bowel disease. These same conditions affect amino acid absorption. The net effect on glycine absorption in this group is unclear, but it is unlikely to affect Tirosint specifically.

Pregnancy

Levothyroxine requirements increase by approximately 25 to 50% during pregnancy (8). Glycine requirements also increase during pregnancy because endogenous synthesis cannot meet fetal collagen demands. The combination is not contraindicated, but both the glycine dose and the levothyroxine dose should be reviewed by the obstetric endocrinologist at each trimester. TSH targets during pregnancy are tighter: the Endocrine Society recommends TSH <2.5 mIU/L in the first trimester (9).

Monitoring Protocol When Taking Both

A clear monitoring schedule reduces uncertainty. The following is appropriate for a patient stabilized on Tirosint who adds glycine supplementation.

Baseline (before starting glycine): Obtain TSH and free T4. Record fasting glucose if diabetic. Document current sleep quality and fatigue scores using a validated instrument such as the Multidimensional Fatigue Inventory (MFI-20).

4 weeks: Check fasting glucose (diabetic patients only). Note any changes in sleep quality or fatigue subjectively.

6 to 8 weeks: Repeat TSH and free T4. Compare to baseline. If TSH has shifted outside the target range, evaluate the Tirosint dose before assuming glycine is responsible; dose variability from day-to-day adherence differences is a more common cause of TSH drift than supplement interference.

Ongoing: Resume the standard annual or semi-annual TSH monitoring schedule once stability is confirmed.

What the Guidelines Say

No major thyroid guideline (American Thyroid Association, Endocrine Society, or British Thyroid Association) has issued a specific statement on glycine and levothyroxine as of early 2025. That silence reflects the low perceived risk, not an oversight.

The ATA's 2014 hypothyroidism management guidelines state directly: "Certain dietary supplements and medications interfere with levothyroxine absorption or metabolism and should be taken at separate times." (5) The listed interfering agents include calcium carbonate, ferrous sulfate, proton-pump inhibitors, bile acid sequestrants, and several antacids. Glycine is not on that list.

The Natural Medicines Database, a standard clinical reference used by pharmacists, classifies the glycine-levothyroxine interaction as "unknown" due to insufficient evidence, which is not the same as "harmful." An "unknown" classification means no data exist confirming either safety or risk, not that risk has been established.

Should You Tell Your Doctor You're Taking Glycine?

Yes. Full stop. This is not about glycine being dangerous with Tirosint. The reason is simpler: any supplement that affects sleep, glucose, or energy perception can confuse the clinical picture during levothyroxine titration. Your prescriber needs an accurate baseline to interpret your TSH trend correctly.

Bring the supplement label to your appointment. Note the dose, the timing, and how long you have been taking it. If your provider is unfamiliar with glycine, you can reference the 2012 sleep trial (3) and the 2016 glucose trial (4) as the core evidence base.

"Patients on levothyroxine who wish to take supplements should always inform their prescribing clinician, even when no formal interaction is known. The narrow therapeutic index of thyroid hormone means that small, indirect effects can still move TSH outside the target range over time." This reflects the consistent position of endocrinologists managing thyroid replacement therapy.

Key Takeaways for Clinicians

A brief summary for the prescriber reviewing this case:

• Glycine at 3 to 5 g/day poses no confirmed direct pharmacokinetic risk to levothyroxine gel-cap absorption based on current mechanistic and transporter data.
• The pharmacodynamic overlap (sedation, glucose modulation) is the actionable concern, specifically in diabetic or CNS-polypharmacy patients.
• Natural timing separation (morning Tirosint, evening glycine) eliminates practical absorption concerns for most patients.
• A TSH recheck at 6 to 8 weeks after starting glycine provides adequate safety monitoring.
• Patients with TSH suppression targets (thyroid cancer surveillance) or pregnancy require tighter monitoring intervals regardless.

In patients with post-thyroidectomy hypothyroidism maintained on Tirosint with a TSH target of <0.1 mIU/L, repeat TSH at 6 weeks after any supplement change, not 3 months.